{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:08:47Z","timestamp":1770923327636,"version":"3.50.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1586\/14737167.8.6.563","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T10:46:40Z","timestamp":1229597200000},"page":"563-573","source":"Crossref","is-referenced-by-count":5,"title":["Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost\u2013effectiveness"],"prefix":"10.1586","volume":"8","author":[{"given":"Pedro","family":"Plans","sequence":"first","affiliation":[{"name":"Direcci\u00f3 General de Salut P\u00fablica, Departament de Salut, Generalitat de Catalunya, Roc Boronat 83\u201395, Barcelona 08005, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01241-6"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1333"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2007.2.1.41"},{"key":"e_1_3_2_5_1","first-page":"1","volume":"57","author":"Fiore","year":"2008","unstructured":"Fiore AE, Shay DK, Broder K et al.; CDC Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.57(RR07), 1\u201360 (2008).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"e_1_3_2_6_1","first-page":"1","volume":"58","year":"2003","unstructured":"NHS. National Institute of Clinical Excellence in the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Technol. Appraisal58, 1\u201330 (2003).","journal-title":"Technol. Appraisal"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.05.009"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/0036554021000026999"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7401.1235"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900312"},{"key":"e_1_3_2_11_1","first-page":"21","volume":"15","year":"2006","unstructured":"Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int.15, 21\u201330 (2006).","journal-title":"Prescrire Int."},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJMc062989","volume":"356","author":"Saito","year":"2007","unstructured":"Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005\u20132006. N. Engl. J. Med.356, 312\u2013313 (2007).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-77011-1_8"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011023431801"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/381128"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/cdli.4.4.491-492.1997","volume":"4","author":"Gross","year":"1997","unstructured":"Gross PA, Russo C, Dran S et al. Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin. Diag. Lab. Immunol.4, 491\u2013492 (1997).","journal-title":"Clin. Diag. Lab. Immunol."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1995.tb06246.x"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2307\/30142367"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-5-732"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00002512-199405010-00002","volume":"5","author":"Guay","year":"1994","unstructured":"Guay DR. Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective. Drugs Aging5, 8\u201319 (1994).","journal-title":"Drugs Aging"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50153.x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00141-8"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/501727"},{"key":"e_1_3_2_24_1","first-page":"37","volume":"27","author":"Parker","year":"2001","unstructured":"Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can. Commun. Dis. Rep.27, 37\u201340 (2001).","journal-title":"Can. Commun. Dis. Rep."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200017060-00007"},{"key":"e_1_3_2_26_1","first-page":"979","volume":"35","author":"Armstrong","year":"2000","unstructured":"Armstrong E, Khan Z, Perry A, Hons M, Perri L. The cost\u2013effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary35, 979\u2013989 (2000).","journal-title":"Formulary"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119030-00007"},{"key":"e_1_3_2_28_1","unstructured":"Husereau D Brady B McGeer A. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment. Canadian Coordinating Office for Health Technology Assessment ON Canada (2001)."},{"key":"e_1_3_2_29_1","unstructured":"Brady B Mc Auley L Shukla V. Economic evaluation of zanamivir for the treament of influenza. Canadian Coordinating Office for Health Technology Assessment ON Canada (2001)."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/324491"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01222-6"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-4-200208200-00005"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00154-8"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjmed.2004.03.044","volume":"118","author":"Rothberg","year":"2005","unstructured":"Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost\u2013effectiveness analysis. Am. J. Med.118, 70\u201379 (2005).","journal-title":"Am. J. Med."},{"key":"e_1_3_2_35_1","first-page":"1","volume":"6","author":"Bruls","year":"2002","unstructured":"Bruls A, Clark W, Stewart T et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol. Assess.6, 1\u201387 (2002).","journal-title":"Health Technol. Assess."},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00007"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2003.20822.x"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00019053-200321030-00006","volume":"21","author":"Schwarzinger","year":"2003","unstructured":"Schwarzinger M, Housset B, Carrat F. Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost\u2013benefit analysis. Pharmacoeconomics21, 215\u2013224 (2003).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2003.00213.x"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta7350"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1007\/s10198-005-0297-y","volume":"6","author":"Sander","year":"2005","unstructured":"Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuraminidase inhibitors: cost\u2013effectiveness and cost\u2013utility in healthy adults in the United Kingdom. Eur. J. Health Econ.6, 2442\u20132452 (2005).","journal-title":"Eur. J. Health Econ."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624040-00007"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53162.x"},{"key":"e_1_3_2_44_1","unstructured":"Roche Tamiflu (oseltamivir) influenza prophylaxis: Achieving Clinical Excellence in Influenza Prophylaxis. Roche submission to the National Institute for Health and Clinical Excellence (2007)."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00332-1"},{"key":"e_1_3_2_46_1","author":"Tappenden","year":"2008","unstructured":"Tappenden P, Jackson R, Cooper K et al. Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67). Health Tech. Assess. (2008) (In Press).","journal-title":"Health Tech. Assess."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39308.560069.BE"},{"key":"e_1_3_2_48_1","unstructured":"Cost\u2013Effectiveness in Health and Medicine. Gold MR Siegel JE Russell LB Weinstein MC (Eds). Oxford University Press NY USA (1996)."},{"key":"e_1_3_2_49_1","unstructured":"Drummond MF Sculper MJ Torrance GW O\u2019Brien BJ. Methods For The Economic Evaluation Of Health Care Programmes. Oxford University Press Oxford UK (1997)."},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/mr.56.1.152-179.1992"},{"key":"e_1_3_2_51_1","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1126\/science.7038875","volume":"92","author":"Palese","year":"1982","unstructured":"Palese P, Young JF. Variation of influenza A, B and C viruses. Science92, 1468\u20131474 (1982).","journal-title":"Science"},{"key":"e_1_3_2_52_1","unstructured":"WHO Guidelines on the use of vaccines and antivirals during influenza pandemics. WHO Geneva Switzerland (2004)."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1402.070478"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737167.8.6.563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:07:41Z","timestamp":1770919661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737167.8.6.563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1586\/14737167.8.6.563"],"URL":"https:\/\/doi.org\/10.1586\/14737167.8.6.563","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}